Skip to content

US · ACRV · BIOTECHNOLOGY

Acrivon Therapeutics, Inc. Common Stock (ACRV) intrinsic value and stock valuation

$1.15as of 2026-11-21 · Mkt cap 70.19M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Acrivon Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values ACRV with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACRV’s statements →

Acrivon Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02472 acrivon.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-77.91M
20202025
Free cash flow
-$-65.33M
20202025
Total equity
$112.5M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-84.11M-$-89.2M-$-67.24M-$-32.66M-$-16.18M
Net income-$-77.91M-$-80.56M-$-60.39M-$-31.17M-$-16.24M
EPSd-$-2.02M-$-2.1M-$-2.74M-$-1.42M-$-1.26M
Operating cash flow-$-63.66M-$-65.67M-$-42.64M-$-30.12M-$-13.98M
Capital expenditure-$-1.67M-$-2.77M-$-1.29M-$-2.17M-$-240K
Free cash flow-$-65.33M-$-68.44M-$-43.93M-$-32.28M-$-14.22M
Total assets$129.7M$196.6M$138.3M$181.2M$106.6M
Total debt$2.71M$3.65M$4.64M$4.96M$5.63M
Net debt-$-38.79M-$-36.17M-$-31.37M-$-24.56M-$-93.97M
Total equity$112.5M$176.8M$121.2M$170.5M-$-23.81M
Cash and short-term investments$118.6M$179.5M$127.5M$127.8M$99.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$1.36M$1.01M$540K$0.00$0.00
Gross profit-$-1.36M-$-1.01M-$-540K$0.00$0.00
Research and development expenses$60M$64M$45.5M$24M$13.7M
Selling, general and administrative expenses$24.1M$25.2M$21.2M$8.71M$2.47M
Other expenses-$-1.36M-$-1.01M$0.00$0.00$0.00
Operating expenses$82.8M$88.2M$66.7M$32.7M$16.2M
Cost and expenses$84.1M$89.2M$67.2M$32.7M$16.2M
Interest income$6.48M$9.2M$7.04M$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.36M$1.01M$540K$360K$40K
Ebitda-$-76.55M-$-79.55M-$-59.85M-$-30.8M-$-16.21M
Operating income-$-84.11M-$-89.2M-$-67.24M-$-32.66M-$-16.18M
Total other income/expenses, net$6.21M$8.64M$6.85M$1.49M-$-60K
Income before tax-$-77.91M-$-80.56M-$-60.39M-$-31.17M-$-16.24M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-77.91M-$-80.56M-$-60.39M-$-31.17M-$-16.24M
Weighted average shares outstanding$38.5M$38.3M$22.1M$21.9M$12.9M
Weighted average diluted shares outstanding$38.5M$38.3M$22.1M$21.9M$12.9M
Balance sheet
20252024202320222021
Cash and short-term investments$118.6M$179.5M$127.5M$127.8M$99.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$120.4M$181.6M$129.7M$132.1M$100.4M
Property, plant and equipment, net$7.42M$8.03M$7.91M$6.86M$5.79M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$5.09M$0.00$41.9M$0.00
Total non-current assets$9.27M$15M$8.57M$49.1M$6.18M
Total assets$129.7M$196.6M$138.3M$181.2M$106.6M
Accounts payable$2.28M$760K$5.05M$900K$960K
Short-term debt$1.17M$1.06M$880K$730K$660K
Deferred revenue$0.00$0.00$0.00$70K$70K
Total current liabilities$15.7M$17.2M$13.3M$6.52M$2.91M
Long-term debt$1.54M$2.59M$3.77M$4.24M$4.96M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.54M$2.59M$3.77M$4.24M$127.5M
Capital lease obligations$2.71M$2.59M$4.64M$4.96M$5.63M
Total liabilities$17.2M$19.8M$17.1M$10.8M$130.4M
Common stock$30K$30K$20K$20K$0.00
Retained earnings-$-274.88M-$-196.98M-$-116.42M-$-56.03M-$-24.86M
Accumulated other comprehensive income (loss)$110K$450K-$-80K-$-100K$0.00
Total equity$112.5M$176.8M$121.2M$170.5M-$-23.81M
Total investments$77.1M$144.8M$91.4M$140.1M$0.00
Total debt$2.71M$3.65M$4.64M$4.96M$5.63M
Net debt-$-38.79M-$-36.17M-$-31.37M-$-24.56M-$-93.97M
Cash flow statement
20252024202320222021
Net income-$-77.91M-$-80.56M-$-60.39M-$-31.17M-$-16.24M
Depreciation and amortization$920K$1.01M$540K$360K$40K
Stock-based compensation$14.7M$14.3M$11.6M$2.19M$500K
Change in working capital-$-2.43M$2.44M$8.14M-$-1.53M$330K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.54M-$-3.59M$3.61M-$-240K$800K
Net cash provided by operating activities-$-63.66M-$-65.67M-$-42.64M-$-30.12M-$-13.98M
Investments in property, plant and equipment-$-1.67M-$-2.77M-$-1.29M-$-2.17M-$-240K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$66.1M-$-51.77M$50.7M-$-141.68M-$-240K
Common stock issued$0.00$70M-$-260K$104.5M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-750K$121M-$-1.55M$101.7M$112.2M
Net change in cash$1.69M$3.59M$6.52M-$-70.08M$98M
Cash at end of period$41.7M$40M$36.4M$29.9M$100M
Operating cash flow-$-63.66M-$-65.67M-$-42.64M-$-30.12M-$-13.98M
Capital expenditure-$-1.67M-$-2.77M-$-1.29M-$-2.17M-$-240K
Free cash flow-$-65.33M-$-68.44M-$-43.93M-$-32.28M-$-14.22M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Acrivon Therapeutics, Inc. Common Stock

        Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

        CEO
        Peter Blume-Jensen
        Employees
        76
        Beta
        1.83

        Explore

        Frequently asked questions

        What is the intrinsic value of Acrivon Therapeutics, Inc. Common Stock (ACRV)?

        InvestorsCraft does not currently publish an intrinsic value for ACRV. How the IC value is calculated.

        Is ACRV undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACRV at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.